Objectives. To investigate the hypothesis that a novel biodegradable polymer-coated cobaltchromium (CoCr) sirolimus-eluting stent (BP-SES) is noninferior in safety and efficacy outcomes to a durable polymer (DP)-SES. Background. No randomized trials have compared safety and efficacy of BP-versus DP-SES on similar CoCr platforms thereby isolating the effect of the polymer type. Methods. In this prospective, single blinded, randomized trial conducted in 32 Chinese sites, 2737 patients eligible for coronary stenting were treated with BP-or DP-SES in a 2:1 ratio. The primary endpoint was 12-month target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TVMI), or clinically indicated target lesion revascularization (TLR). Secondary endpoints included TLF components, and definite/probable stent thrombosis. Results. At 12 months, the difference in the primary endpoint of TLF between BP-SES (6.3%) and DP-SES (6.1%) groups was 0.25% (95% confidence interval: -1.67% to 2.17%, P for noninferiority=0.0002), demonstrating noninferiority of BP-SES to DP-SES. Individual TLF components of cardiac death (0.7% vs. 0.6%, P=0.62), TVMI (3.6% vs. 4.3%, P=0.39), and clinically indicated TLR (2.6% vs. 2.2%, P=0.50) were similar, as were low definite/probable stent thrombosis rates (0.4% vs. 0.6%, P=0.55).
Introduction
Drug-eluting stents (DES) using biodegradable polymers (BP) have been designed to overcome long-term adverse vascular reactions related to durable polymer (DP) (1) (2) (3) .
Despite theoretical advantages of BP in lowering thrombotic risk, whether these translate into real reductions in clinical outcomes remain unsettled. We previously demonstrated a satisfactory safety profile of BP-DES with low rates of overall stent thrombosis (4) . Similarly, a pooled analysis of the ISAR TEST-3, ISAR TEST-4, and LEADERS trials showed that BP-DES were associated with a significantly lower rate of very late definite stent thrombosis from 1 to 4 years compared with DP-DES (5) . However, the recent Scandinavian Organization for Randomized Trials with Clinical Outcome (SORT OUT) V trial reported that BP biolimus-eluting stents (BES) did not show noninferiority compared with DP sirolimus-eluting stents (SES) at 1-year follow-up (6) . No randomized trials have compared safety and efficacy of BP-versus DP-SES on similar cobalt-chromium (CoCr) platforms, thereby isolating the effect of the BP from other stent-related effects. We therefore designed a large-scale randomized trial comparing a novel CoCr BP-SES (TIVOLI TM , EssenTech, Beijing, China) and the CoCr DP-SES (FIREBIRD 2 TM , MicroPort, Shanghai, China) powered to evaluate noninferiority in clinical efficacy outcomes.
Methods
Patients. Between October，2012, and June, 2013, we recruited adult patients with chronic, stable coronary artery disease or acute coronary syndromes, including myocardial infarction (MI) with or without ST-segment elevation at 32 centers in China. Patients were eligible if they were over 18 years old, and had at least one coronary lesion with stenosis of >70% in a vessel with reference diameter of 2.5 to 4.0 mm. No restriction was placed on total number of treated lesions, treated vessels, lesion length, or number of stents implanted. Patients with multivessel disease must receive complete revascularization within 30 days using same study M A N U S C R I P T
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stents if needed. Exclusion criteria were known intolerance to a study drug, metal alloys, or contrast media; life expectancy less than one year; restenosis lesions; stent implantation within one year; left ventricular ejection fraction <40%; severe renal or hepatic dysfunction; hemodynamic instability; planned surgery within 6 months after index procedure; childbearing potential within one year; clinical indications of inability to tolerate dual antiplatelet therapy (DAPT) for 12 months; inability to provide written informed consent; and participation in another trial before reaching the primary endpoint.
The study complied with the provisions of the Declaration of Helsinki, and the study protocol was approved by the institutional review board at each study center. All patients provided written informed consent.
Study design. I-LOVE-IT 2 Trial was a prospective, multicenter, randomized, assessorblinded, noninferiority study comparing BP-SES with DP-SES. Patients scheduled for percutaneous coronary intervention (PCI) using DES were to be enrolled with fewer exclusion criteria.
Patients were randomly assigned to undergo PCI with either BP-SES or DP-SES in a 2:1 ratio. Patients who were randomized to BP-SES group were additionally re-randomized to a 6-month DAPT group or 12-month DAPT group in a 1:1 ratio (data not available in this 1 year follow-up report). Randomization was performed after angiogram by a web-based allocation system and was stratified by center. Angiograms were reviewed by a blinded independent core laboratory (CCRF, Beijing, China), and all adverse events were adjudicated by a blinded clinical events committee. (ClinicalTrials.gov identifier: NCT 01681381)
Procedures. Comparison of specifications between BP-SES and DP-SES is shown in table 1. Both are low-profile, thin strut CoCr alloy stents with same anti-proliferative drug (7, 8) . Balloon angioplasty and stent implantation were performed according to standard techniques; direct stenting (without previous balloon dilatation) was allowed. No mixture of
type of stents was permitted for a given patient unless the operator was unable to insert the study stent, in which case crossover to another nonstudy device of the operator's choice was possible. Staged procedures were permitted, which were defined as procedures planned at the time of index procedure and performed within 30 days with the same type of study stent. In the case of unplanned revascularization procedures requiring stent implantation, it was recommended that physicians use the same type of study stent.
Procedural anticoagulation was achieved with unfractionated heparin at a dose 70 to 100 IU per kilogram of body weight, and activated clotting time was maintained at 250 seconds or above; the use of glycoprotein IIb/IIIa inhibitors was left to operator's discretion. A loading dose of 300 mg of aspirin and 300 mg of clopidogrel was administered before all procedures. All patients were discharged with a prescription for at least 100 mg of aspirin indefinitely and 75 mg of clopidogrel for a minimum of 6 months after index procedure.
Qualitative and quantitative coronary angiography (including SYNTAX score and residual SYNTAX score) was centrally evaluated at CCRF using QAngio XA Version 7.3
Analysis Software (Medis Medical Imaging System Inc., Leiden, The Netherlands).
Endpoints. The primary endpoint was 12-month target lesion failure (TLF), a composite of cardiac death, target vessel myocardial infarction (TVMI), or clinically indicated target lesion revascularization (TLR). Secondary endpoints included TLF components, device/lesion/procedure success rates, definite/probable stent thrombosis, and patientoriented composite endpoint (PoCE, including composite of all-cause death, all MI and any revascularization).
We defined cardiac death as any death due to an evident cardiac cause, any death related to PCI, unwitnessed death, or death from unknown causes. Periprocedural MI in patients without infarction at baseline was defined as any increase in creatine kinase concentration to more than double normal value (defined according to the local laboratory's standard) with M A N U S C R I P T A C C E P T E D Patients were followed up by telephone or hospital visit at 1, 6, 9, and 12 months and will continue to undergo follow-up annually for 5 years.
Statistical Analysis. Based on previously reported studies, sample size was calculated expecting a 12-month event rate of 8.3% in both groups. The prespecified noninferiority margin for the primary endpoint was 3.7%. With one-sided type I error of 0.025, 2631 patients (1754 and 877 patients in BP-and DP-SES groups, respectively) randomized in a 2:1 ratio would yield at least 90% power to detect non-inferiority. Allowing for up to 5% loss to follow-up, a total of 2790 subjects would need to be enrolled. Noninferiority would be achieved if the upper limit of the one sided 95% confidence interval of the difference is less than the margin.
Categorical variables are reported as counts and percentages, and between-group differences were assessed with Chi-square or Fisher's exact test. Continuous variables are
presented as means ±SD and were compared with the use of a two-sample t-test. The KaplanMeier method was used to calculate time to clinical endpoints, and the log-rank test was used to compare between-group differences. An exploratory Cox regression analysis was used to identify demographic and clinical factors predictive of endpoint. Unless otherwise specified, a two-sided P value of less than 0.05 was considered to indicate statistical significance.
Statistical analysis was performed using SAS software (SAS 9.1.3., SAS Institute, Cary, NC). 
Results
A total of 2737 patients were randomly assigned to receive either BP-SES (n =1829) or DP-SES (n=908) ( Figure 1 ). 14 patients (0.5%) were lost to follow-up before the 12 month cutoff date (11 and 3 patients in the BP-and DP-SES groups, respectively). The two groups of patients were generally well balanced in terms of baseline clinical and lesion characteristics (Tables 2 and 3 ), except that there were more patients with peripheral vascular disease in BP-SES group. QCA analysis and procedural results were similar between the two groups (Table   4 ). Procedural complications occurred in few patients and the device / lesion / procedure success rates were relatively high in both groups. A total of 853 (93.8%) of 909 patients allocated to the 6-month DAPT group after BP-SES implantation actually stopped clopidogrel at 6 months per the protocol. Therefore, a full 1-year clopidogrel plus aspirin treatment was followed in all patients of the DP-SES group and in 50% of patients in the BP-SES group.
At 12 months, primary endpoint TLF difference was 0.25% (95% confidence interval: -1.67% to 2.17%) between the BP-SES group (6.3% (115/1818)) and the DP-SES group (6.1%
(55/905)), demonstrating noninferiority of BP-SES to DP-SES in terms of TLF with a noninferiority margin of 3.7% (P for noninferiority=0.0002) ( For the secondary endpoint of PoCE, there was no significant difference between the BP-SES group and the DP-SES group (BP-SES vs. DP-SES, 9.7% vs. 9.4%, P=0.81) ( Table 5 , (Table 5 ). Rates of definite/probable stent thrombosis were low without significant difference between the two groups (BP-SES vs. DP-SES, 0.4% vs. 0.6% P=0.55) ( Table 5 , Fig. 2F ). In addition, as the major contributor of TVMI, the periprocedural MI was mainly caused by abrupt closure or slow/no flow during the PCI procedure, rather than stent thrombosis. Furthermore, number of patients reaching primary endpoint in each group did not differ significantly between prespecified subgroups (Figure 3 ).
In multivariate Cox regression analyses, emergent PCI for AMI, baseline SYNTAX score, total stent length per patient, and unsuccessful lesion were four independent predictors of TLF (Table 6 ). Stent type was not an independent predictor of TLF.
The main finding of this prospective, randomized, multicenter trial is that BP-SES was noninferior to DP-SES when used in a population with minimal exclusion criteria and assessed at one year follow-up. Moreover, the primary composite endpoint of cardiac death, TVMI, or clinically indicated TLR did not differ significantly between stent types, nor did its individual components or stent thrombosis rates.
This is the first adequately powered trial to compare BP with DP on similar CoCr stents eluting the same sirolimus drug. Following the conduct of the study, based on the observed TLF rate of 6.3% and actual n per group, there is 80% power to exclude a 0.028 noninferiority margin (margin/event ratio 44.5%, same as originally planned). Previous studies comparing BP-vs. DP-DES have reported conflicting results, perhaps in part due to differing base stent platforms and eluting drugs (6, (11) (12) (13) (14) . In the SORT OUT V study, a BP- Furthermore, the BP-DES platform in previous studies (Nobori and BioMatrix Flex) consists of stainless steel with relatively thick struts (120 µm) (17) . In comparison, BP-SES in our study has thinner strut thickness of 80µm. Future efforts to achieve better safety of BP-DES need to focus both on reducing stent strut as well as polymer thickness.
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One of the important results from our study is depicted in the TLF Kaplan-Meier curve ( Fig. 2A) . First, these results are consistent with previous meta-analysis (18) , which showed that although BP-DES are superior to DP-DES in terms of inhibition of neointimal regrowth, no obvious benefit on harder endpoints such as mortality, MI, or revascularization rates are apparent. Second, the two survival curves separated before 6-month follow-up, but approached each other after 6 months. Since only half of BP-SES group received clopidogrel beyond 6 months (per the protocol driven subrandomization), it is possible that the lower level of DAPT utilization in this group may have afforded an increase in event rates within the 6 to 12 month interval of follow-up. This will be appropriately investigated when outcomes data in relation to the DAPT randomization become available. However, long-term follow-up is warranted.
The rates of stent thrombosis were low in both groups, which is not surprising and consistent with previous meta-analysis (19) showing that CoCr-DES reduced stent thrombosis even when compared with bare-metal stents. Previous studies have shown a statistically significant and likely clinically important risk reduction for definite stent thrombosis in favor of BP-DES compared with DP-DES at long-term follow-up (5). For example, five-year results in LEADERS trial showed that BP-DES was associated with a significant reduction in very late (>1 year) definite stent thrombosis (20) . Therefore, longterm follow-up in the study is needed to also clarify benefit of BP-DES on rate of stent thrombosis. Additionally, the optimal duration of DAPT after BP-DES implantation remains controversial. From a post hoc analysis, we recently found that prolonged DAPT (greater than 6 months) after BP-DES implantation increases the risk of bleeding, and is associated with adverse cardiac events at 1-year follow-up (21) . Long-term follow-up will provide valuable data from 6 vs.12 month DAPT randomization in the study.
The present study has some limitations. First, we enrolled only part of the total PCI M A N U S C R I P T
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population at enrolling centers, rather than consecutive patients, and we cannot rule out some selection bias. However, the baseline SYNTAX score of enrolled patients in this study compared favorably with that in previous "all-comer" trials (11, 22) , and low residual SYNTAX score may partly explain lower event rates in this trial. Therefore, we consider that our findings are highly generalizable to patients in everyday clinical practice. Second, composite endpoints were used as primary endpoints in the study, which have wellrecognized limitations that arise from the common practice of weighting all endpoint components equally, irrespective of their relative impact on the life of the patient (23) . Third, the study was not powered enough to evaluate the safety endpoints at 12 months, especially stent thrombosis, warranting longer follow-up or larger trials. Fourth, we used the old universal definition of periprocedural MI, which may overestimate the occurrence of TVMI.
A recent definition of universal MI was an infarction with greater than 5 fold cardiac enzyme elevations. Lastly, although baseline characteristics bias has been well controlled in this randomized trial, there are some differences in procedural characteristics, for example, rates of balloon predilation and postdilation, which might reflect minor difference between two stent platforms. However, those differences were not the predictors of the primary endpoint.
Conclusions
The present I-LOVE-IT 2 trial has demonstrated that the BP-SES is non-inferior in terms of efficacy to DP-SES in clinical practice. Whether BP-SES improves safety with respect to lowering stent thrombosis incidence compared with DP-SES, remains to be shown in longerterm follow-up of this trial or in future studies. BP-SES = biodegradable polymer sirolimus-eluting stent; DP-SES = durable polymer sirolimus-eluting stent; PBMA = poly-n-butyl methacrylate; PEVA = Polyethylene-co-vinyl acetate; PLGA = poly lactide-co-glycolide; SBS = styrene-butadiene block copolymer. 
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Values are mean ± SD or n (%). Values are mean ± SD or n (%).
BP-SES
BP-SES = biodegradable polymer sirolimus-eluting stent; DP-SES = durable polymer sirolimus-eluting stent; SYNTAX = synergy between PCI with TAXUS and cardiac surgery; TIMI = thrombolysis in myocardial infarction; QCA = quantitative coronary angiography.
Complex lesions were defined by presence of at least one of the following lesion characteristics: unprotected left main coronary artery, bifurcation, ostial lesion, total occlusion, severely tortuous or angulated lesion, and moderate to heavy calcification. Values are mean ± SD or n (%).
BP-SES = biodegradable polymer sirolimus-eluting stent; DP-SES = durable polymer sirolimus-eluting stent; SYNTAX = synergy between PCI with TAXUS and cardiac surgery; TIMI = thrombolysis in myocardial infarction; QCA = quantitative coronary angiography. 
